Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene [1]

Journal of Hepatology

Volumn 28, Issue 5, 1998, Pages 909-910

  Wolters, L M M ^a   Honkoop, P ^a   Niesters, H G M ^a   De Man, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; FAMCICLOVIR; LAMIVUDINE;

CHRONIC DISEASE; DRUG EFFICACY; ENZYME ACTIVITY; GENE MUTATION; HEPATITIS B; LETTER; PRIORITY JOURNAL; VIREMIA;

EID: 0031923821     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80243-2     Document Type: Letter

References (7)

1. D Wong A Cheung K O'Rourke C Naylor A Detsky J Heathcote Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B Ann Intern Med 119 1993 312 323
2. F Nevens J Main P Honkoop D Tyrrell J Barber M Sullivan Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study Gastroenterology 113 1997 1258 1263
3. NWY Leung CL Lai YF Liaw TT Chang R Guan DI Tai Lamivudine (100 mg) for 1 year significantly improves necroinflammatory activity and reduces progression in fibrosis stage: results of a placebo-controlled multicentre study in Asia lamivudine for chronic hepatitis B infection Hepatology 26 1997 357
4. MM Bartholomew RW Jansen LJ Jeffers KR Reddy LC Johnson H Bunzendahl Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation Lancet 349 1997 20 22
5. T Aye A Bartholomeusz T Shaw S Bowden A Breschkin McMillan Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation J Hepatol 26 1997 1148 1153
6. HGM Niesters P Honkoop EB Haagsma RA de Man SW Schalm ADME Osterhaus Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment J Infect Dis 1998 In press
7. C Buocher N Cammack P Schipper High-level resistance to (−)-enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus transcriptase Antimicrob Agents Chemother 37 1993 2231 2234